CYT-106

N/A

Report date: 2025/01/26 17:53:55

Base Information

Drug NameCYT-106
Drug Alias NameNKp46 multifunctional engagers (Cytovia Therapeutics/Hebrew University of Jerusalem)anti-NKp46/anti-CD38 bispecific NK-cell engager (Cytovia Therapeutics/Hebrew University of Jerusalem)anti-NKp46/anti-CD38 bispecific antibody (Cytovia Therapeutics/Hebrew University of Jerusalem)CYT-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulatorsNatural cytotoxicity triggering receptor 1 agonists
TargetsNatural cytotoxicity triggering receptor 1Lymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe Hebrew University Of Jerusalem
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Sante Et De La Recherche MedicaleCytovia Therapeutics IncThe Hebrew University Of Jerusalem
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A